Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05804227 · ClinicalTrials.gov registry record · Early Phase 1
Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas
A Early Phase 1 study of Gliomas, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05804227 is a Early Phase 1 study of Gliomas that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants, above the 34-participant average among 3 other Gliomas trials with a reported enrollment target (18% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05804227, a Early Phase 1 study of Gliomas, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if the study drug, ulixertinib, can cross over the blood-brain barrier in patients with recurrent brain tumors
Conditions Studied
Interventions
- DRUG Ulixertinib
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-04-20 |
| Est. Completion | 2027-09-22 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05804227
The ClinicalTrials.gov registry entry for NCT05804227 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 34-participant average among 3 other Gliomas trials with a reported enrollment target (18% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gliomas appearing as the primary indexed condition, and to 1 intervention - of which Ulixertinib is the first listed.
NCT05804227 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05804227 about?
NCT05804227 is a clinical study titled "Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas". To learn if the study drug, ulixertinib, can cross over the blood-brain barrier in patients with recurrent brain tumors
What is the current status of trial NCT05804227?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2023-04-20. Estimated completion is 2027-09-22.
What conditions does trial NCT05804227 study?
This clinical trial studies the following conditions: Gliomas.
What interventions are being tested in trial NCT05804227?
The interventions under investigation include: Ulixertinib (DRUG).
Who is sponsoring clinical trial NCT05804227?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05804227 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gliomas
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors
RECRUITING · NA
-
A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas
COMPLETED · Phase 2
-
Cellular Immunotherapy Study for Brain Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.